Loading…

[18F]-FMISO PET/MRI Imaging Shows Ischemic Tissue around Hematoma in Intracerebral Hemorrhage

Intracerebral hemorrhage (ICH), being the most severe cerebrovascular disease, accounts for 10–15% of all strokes. Hematoma expansion is one of the most important factors associated with poor outcome in intracerebral hemorrhage (ICH). Several studies have suggested that an “ischemic penumbra” might...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmaceutics 2020-12, Vol.17 (12), p.4667-4675
Main Authors: Gómez-Lado, Noemí, López-Arias, Esteban, Iglesias-Rey, Ramón, Díaz-Platas, Lucía, Medín-Aguerre, Santiago, Fernández-Ferreiro, Anxo, Posado-Fernández, Adrián, García-Varela, Lara, Rodríguez-Pérez, Manuel, Campos, Francisco, Del Pino, Pablo, Ruibal, Álvaro, Pardo-Montero, Juan, Castillo, José, Aguiar, Pablo, Sobrino, Tomás
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intracerebral hemorrhage (ICH), being the most severe cerebrovascular disease, accounts for 10–15% of all strokes. Hematoma expansion is one of the most important factors associated with poor outcome in intracerebral hemorrhage (ICH). Several studies have suggested that an “ischemic penumbra” might arise when the hematoma has a large expansion, but clinical studies are inconclusive. We performed a preclinical study to demonstrate the presence of hypoxic–ischemic tissue around the hematoma by means of longitudinal [18F]-fluoromisonidazole ([18F]-FMISO) PET/MRI studies over time in an experimental ICH model. Our results showed that all [18F]-FMISO PET/MRI images exhibited hypoxic–ischemic tissue around the hematoma area. A significant increase of [18F]-FMISO uptake was found at 18–24 h post-ICH when the maximum of hematoma volume is achieved and this increase disappeared before 42 h. These results demonstrate the presence of hypoxic tissue around the hematoma and open the possibility of new therapies aimed to reduce ischemic damage associated with ICH.
ISSN:1543-8384
1543-8392
DOI:10.1021/acs.molpharmaceut.0c00932